Virios Therapeutics

General Information
Business:

We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (“IBS”), chronic fatigue syndrome and functional somatic syndrome. Our lead development candidate (“IMC-1”), is a novel proprietary fixed-dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination antiviral therapy designed to synergistically suppress HSV-1 activation and replication, with the end goal of reducing viral mediated disease burden.

(The Virios Therapeutics IPO was priced at $10, the mid-point of its $9-to-$11 range, on 3 million shares, the same number of shares cited in the prospectus.)

Industry: Pharmaceuticals
Employees: 4
Founded: 2012
Contact Information
Address 44 Milton Avenue Alpharetta, GA 30009
Phone Number (866) 620-8655
Web Address http://www.virios.com
View Prospectus: Virios Therapeutics
Financial Information
Market Cap $78.3mil
Revenues $0 mil (last 12 months)
Net Income $-3.6 mil (last 12 months)
IPO Profile
Symbol VIRI
Exchange NASDAQ
Shares (millions): 3.0
Price range $10.00 - $10.00
Est. $ Volume $30.0 mil
Manager / Joint Managers ThinkEquity (a division of Fordham Financial Management)
CO-Managers -
Expected To Trade: 12/17/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change